↓ Skip to main content

Antibiotic Therapy for Chorioamnionitis to Reduce the Global Burden of Associated Disease

Overview of attention for article published in Frontiers in Pharmacology, March 2017
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
2 X users

Citations

dimensions_citation
14 Dimensions

Readers on

mendeley
78 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Antibiotic Therapy for Chorioamnionitis to Reduce the Global Burden of Associated Disease
Published in
Frontiers in Pharmacology, March 2017
DOI 10.3389/fphar.2017.00097
Pubmed ID
Authors

Clark T. Johnson, Rebecca R. Adami, Azadeh Farzin

Abstract

Chorioamnionitis is associated with significant maternal and neonatal morbidity and mortality throughout the world. In developed countries, great progress has been made to minimize the impact of chorioamnionitis, through timely diagnosis and appropriate treatment. In the global setting, where many women deliver outside the healthcare facilities, this diagnosis is frequently overlooked and not properly treated. In addition to its impact on maternal health, a significant proportion of neonatal morbidity and mortality can be prevented by both recognition and access to readily available treatment. With the increasing focus on saving the most vulnerable members of society, we echo the need for providing parturient women with suspected chorioamnionitis universal access to appropriate therapy. We describe known effective antibiotic therapies for chorioamnionitis and provide an overview of additional potential antimicrobial treatments that might be effectively implemented in areas with limited access to care.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 78 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 78 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 11 14%
Other 8 10%
Student > Ph. D. Student 6 8%
Researcher 6 8%
Student > Postgraduate 5 6%
Other 17 22%
Unknown 25 32%
Readers by discipline Count As %
Medicine and Dentistry 29 37%
Pharmacology, Toxicology and Pharmaceutical Science 3 4%
Immunology and Microbiology 3 4%
Nursing and Health Professions 3 4%
Biochemistry, Genetics and Molecular Biology 2 3%
Other 8 10%
Unknown 30 38%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 June 2022.
All research outputs
#18,362,712
of 23,588,018 outputs
Outputs from Frontiers in Pharmacology
#7,531
of 17,216 outputs
Outputs of similar age
#222,652
of 308,964 outputs
Outputs of similar age from Frontiers in Pharmacology
#99
of 205 outputs
Altmetric has tracked 23,588,018 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 17,216 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.0. This one is in the 48th percentile – i.e., 48% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 308,964 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 23rd percentile – i.e., 23% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 205 others from the same source and published within six weeks on either side of this one. This one is in the 44th percentile – i.e., 44% of its contemporaries scored the same or lower than it.